Paul E. Oberstein, J. Randolph Hecht, Kanwal Raghav, Filippo Pietrantonio, Dirk Arnold, Víctor Moreno, Eric Van Cutsem, Rozita Abdul Malik, Yong Sang Hong, Myung Ah Lee, Harvey Yu-Li Su, Jeeyun Lee, Sreenivasa Chandana, Marcia Cruz-Correa, Ying Yuan, Azura Ahmad, Kuan-Ming Lai, Hung-Chih Hsu, Eric Xueyu Chen, Elena Elez, Chia-Chi Lin, Carlos Lopez, Hans Prenen, Susana Roselló-Keränen, Hector Velez, Yu-Min Yeh, Volker Heinemann, Cathy Eng, Seung-Hoon Beom, Sabine Tejpar, Sanjib Chowdhury, Xuesong Lyu, Medha Kamat, Joshua C. Curtin, Bharvin Patel, John Xie, Rianka Bhattacharya, Robert W. Schnepp, Emrullah Yilmaz, Ryota Iwasawa, Mahesh Daksh, Patricia Lorenzini, Meena Thayu, Mahadi Baig, Han Sang Kim, Sae-Won Han. "Amivantamab Monotherapy in Chemorefractory
                    <i>RAS</i>
                    /
                    <i>BRAF</i>
                    Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study." Journal of Clinical Oncology (2026). https://doi.org/10.1200/jco-25-02187